Prospective Evaluation of MGMT -Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

• Published in: Current oncology (Toronto) Vol. 30; no. 2; pp. 1381 - 1394
• Main Authors: Brighi, Nicole, Lamberti, Giuseppe, Andrini, Elisa, Mosconi, Cristina, Manuzzi, Lisa, Donati, Giada, Lisotti, Andrea, Campana, Davide
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 18.01.2023; MDPI AG
• Subjects: Antineoplastic Agents, Alkylating - therapeutic use; biomarkers; chemotherapy; DNA Modification Methylases - therapeutic use; DNA Repair Enzymes - therapeutic use; epigenetic; gastroenteropancreatic; Humans; Methylation; neuroendocrine neoplasms; Neuroendocrine Tumors; Prospective Studies; Temozolomide - therapeutic use; Tumor Suppressor Proteins; neuroendocrine neoplasms; epigenetic; chemotherapy; biomarkers; gastroenteropancreatic
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol30020106

Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin. The predictive role of MGMT-promoter methylation in this setting is controversial. We sought to prospectively evaluate the MGMT-promoter methylation status ability to predict outcomes to TEM-based chemotherapy in patients with NET. A single-center, prospective, observational study has been conducted at the ENETS Center-of-Excellence Outpatient Clinic of the IRCCS Policlinico Sant'Orsola-Malpighi in Bologna, Italy. Patients with advanced, gastro-entero-pancreatic or lung well-differentiated NETs candidate to TEM-based chemotherapy and with available tumor samples for MGMT-promoter methylation assessment were included. The MGMT-promoter methylation status was analyzed by using pyrosequencing. The primary endpoint was progression-free survival (PFS) by the MGMT-promoter methylation status. Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Survival outcomes were compared by restricted mean survival time (RMST) difference. Of 26 screened patients, 22 were finally enrolled in the study. The most frequent NET primary sites were the pancreas (64%) and the lung (23%). MGMT promoter was methylated in five tumors (23%). At a median follow-up time of 47.2 months (95%CI 29.3-89.7), the median PFS was 32.8 months (95%CI 17.2-NA), while the median OS was not reached. Patients in the methylated MGMT group, when compared to those in the unmethylated MGMT group, had longer PFS (median not reached [95%CI NA-NA] vs. 30.2 months [95%CI 15.2-NA], respectively; RMST = 0.005) and OS (median not reached [95%CI NA-NA] vs. not reached [40.1-NA], respectively; RMST = 0.019). After adjusting for confounding factors, the MGMT-promoter methylation status was independently associated to the PFS. Numerically higher ORR (60% vs. 24%; = 0.274) and DCR (100% vs. 88%; = 1.00) were observed in the methylated vs. unmethylated MGMT group. TEM-based chemotherapy was well-tolerated (adverse events grade ≥3 < 10%). In this prospective study, MGMT-promoter methylation predicted better outcomes to TEM-based chemotherapy in patients with NET.